Titre : | Relative bioavailability of different buprenorphine formulations under chronic dosing conditions |
Titre traduit : | (Biodisponibilité relative de différentes formules de buprénorphine dans des conditions d'administration chronique) |
Auteurs : | E. C. STRAIN ; D. E. MOODY ; K. B. STOLLER ; S. L. WALSH ; G. E. BIGELOW |
Type de document : | Périodique |
Année de publication : | 2004 |
Format : | 37-43 / fig. |
Note générale : |
Drug and Alcohol Dependence, 2004, 74, (1), 37-43 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BUPRENORPHINE ; NALOXONE ; PHARMACOCINETIQUE ; DOSE-REPONSE ; TRAITEMENT DE MAINTENANCE |
Résumé : |
ENGLISH : Background: Buprenorphine is an approved medication for the treatment of opioid dependence. Three sublingual formulations have been used at various times during its development-a solution containing alcohol, tablets containing buprenorphine alone, and tablets containing buprenorphine plus naloxone. This study compared the relative buprenorphine bioavailability of these different formulations. Methods: Outpatient volunteers (N = 10) were maintained for 14 days of daily administration on each formulation; the dose of buprenorphine (8 mg) was constant across formulations. Blood samples were collected and tested for buprenorphine and norbuprenorphine concentrations after 7 and 14 days maintenance on each formulation. Serial samples were collected before and for 6 h after a daily dose of each formulation. Results: Peak buprenorphine concentrations (Cmax) and area under the curve (AUC) for the 6 h interval (AUCo-6) were highest for the solution and lowest for buprenorphine alone tablets; values for combination tablets were more similar to those for solution. Differences between formulations were less pronounced at day 14 than day 7. There was considerable between-subject variability in concentrations produced. Conclusions: These results suggest there may be greater bioavailability of buprenorphine/naloxone versus buprenorphine alone tablets, and that the bioavailability of buprenorphine from the former is very similar to that seen with solution after 2 weeks of stabilization on each formulation. (Review's abstract.) |
Note de contenu : | fig. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 25 |
Affiliation : |
Dept. Psychiatr. Behav. Sci., J. Hopkins Univ. Sch. Med., 5510 Nathan Shock Drive, Baltimore, MD 21224 Etats-Unis. United States. |
Numéro Toxibase : | 804616 |
Centre Emetteur : | 08 CAS Strasbourg |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil